518044-32-1 1-羟基-3,6,9,12-四氧杂十五烷-15-酸叔丁酯

危险性质：非危险化学品

• 靶点 Non-cleavable Alkyl/ether PEGs
• 体外研究 ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

医药

合成路线 1（1. 合成：518044-32-1）

产率：82% 合成条件：With sodium In tetrahydrofuran at 20℃; 实验步骤：向四氢乙二醇（40.61mL; 45.64g; 235mmol）的无水溶液中加入。加入THF（125mL），一片钠（1/4 cm）。在钠完全反应后，在20分钟内逐滴加入丙烯酸叔丁酯（11.98mL; 10.57g; 82.5mmol），并将所得溶液在室温下搅拌过夜。用NaOH溶液（1N）将pH调节至7-8并真空除去溶剂。将残余物溶于饱和NaHCO 3 NaCl溶液（75mL），用EtOAc（3×100mL）萃取。将合并的有机层用MgSO 4干燥，蒸发溶剂后，得到叔丁基-15-羟基-4,7,10,13-四氧杂十五烷酸酯（21.87g; 67.8mmol;基于叔丁基丙烯酸酯的82％），为无色油状物。 。 1H-NMR（500MHz，氯仿-c /，TMS）δ[ppm] = 3.77-3.57（m，18H; OCH2）; 3.01（bs，1H，OH）; 2.51（t，2H，J = 6.6Hz，CH2COO'Bu）; 1.45（s，9H，C（CH3）3）; 13C {1H} -NMR（126MHz，氯仿-c /，TMS）δ[ppm] = 171.1（COO）; 80.7（C（CH3）3）; 72.6 / 70.8 / 70.7 / 70.6 / 70.5 / 67.0（OCH2）; 61.9（HOCH2）; 36.4（CH2CO）; 28.2（C（CH3）3）。 参考文献：

• [1] Synthetic Communications, 2004, vol. 34, # 13, p. 2425 - 2432 [2] Patent: WO2016/146638, 2016, A1. Location in patent: Page/Page column 20 [3] Patent: WO2017/147542, 2017, A2. Location in patent: Paragraph 00162 [4] Patent: WO2018/89373, 2018, A2. Location in patent: Paragraph 0638-0639 [5] Tetrahedron, 2011, vol. 67, # 12, p. 2251 - 2259 [6] Journal of Medicinal Chemistry, 2004, vol. 47, # 20, p. 4802 - 4805 [7] Carbohydrate Research, 2007, vol. 342, # 3-4, p. 541 - 557 [8] Journal of Chemical Research, 2016, vol. 40, # 6, p. 368 - 370 [9] Advanced Synthesis and Catalysis, 2012, vol. 354, # 17, p. 3259 - 3264 [10] Patent: WO2005/112919, 2005, A2. Location in patent: Page/Page column 150 [11] Patent: WO2012/166560, 2012, A1. Location in patent: Page/Page column 163; 168 [12] Patent: WO2013/68874, 2013, A1. Location in patent: Page/Page column 20 [13] Patent: WO2013/192360, 2013, A1. Location in patent: Paragraph 00458; 00479 [14] Patent: WO2013/185117, 2013, A1. Location in patent: Paragraph 00444 [15] Synthetic Communications, 2007, vol. 37, # 11, p. 1899 - 1915 [16] Patent: CN107235848, 2017, A. Location in patent: Paragraph 0021